Latest Period
Q4 2025
Security Snapshot
Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) Institutional Ownership
CUSIP: 90400D108
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
284
Shares (Excl. Options)
93,871,464
Price
$23.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- RARE on Nasdaq
- Shares outstanding
- 98,367,418
- Price per share
- $22.87
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 93,871,464
- Total reported value
- $2,156,995,771
- % of total 13F portfolios
- 0%
- Share change
- -1,662,673
- Value change
- -$89,024,892
- Number of holders
- 284
- Price from insider filings
- $22.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RARE - Ultragenyx Pharmaceutical Inc. - Common Stock is tracked under CUSIP 90400D108.
- 284 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 284 to 74 between Q4 2025 and Q1 2026.
- Reported value moved from $2,156,995,771 to $165,488,430.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 284 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 90400D108?
CUSIP 90400D108 identifies RARE - Ultragenyx Pharmaceutical Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90400D108:
Significant Owners of Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | $113,343,858 | 5,410,208 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| BlackRock, Inc. | 5.1% | $183,098,959 | 4,820,931 | BlackRock, Inc. | 31 Mar 2025 | |||
| SANDS CAPITAL MANAGEMENT, LLC | 4.7% | $163,238,154 | 4,298,003 | SANDS CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| FMR LLC | 3.5% | -60% | $77,001,475 | -$106,192,081 | 3,347,890 | -58% | FMR LLC | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.7% | $93,337,483 | 2,457,543 | Wellington Management Group LLP | 31 Dec 2024 |
As of 31 Dec 2025, 284 institutional investors reported holding 93,871,464 shares of Ultragenyx Pharmaceutical Inc. - Common Stock (RARE). This represents 95% of the company’s total 98,367,418 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| VANGUARD GROUP INC | 10% | 10,263,815 | +1.3% | 0% | $236,067,745 |
| BlackRock, Inc. | 6.7% | 6,631,554 | +3.2% | 0% | $152,525,742 |
| STATE STREET CORP | 4.4% | 4,303,046 | +17% | 0% | $98,970,058 |
| JPMORGAN CHASE & CO | 4% | 3,974,030 | -0.93% | 0.01% | $91,402,705 |
| SANDS CAPITAL MANAGEMENT, LLC | 3.5% | 3,485,724 | -7.5% | 0.24% | $80,171,652 |
| RTW INVESTMENTS, LP | 3% | 3,000,139 | -7.9% | 0.69% | $69,003,197 |
| BAKER BROS. ADVISORS LP | 2.8% | 2,772,692 | 0% | 0.37% | $63,771,916 |
| FMR LLC | 2.7% | 2,666,249 | -63% | 0% | $61,323,732 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.5% | 2,461,910 | +27% | 0.01% | $56,623,930 |
| CITADEL ADVISORS LLC | 2.4% | 2,326,125 | +603% | 0.04% | $53,500,875 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.1% | 2,019,000 | 0% | 1.2% | $46,437,000 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 2% | 1,965,084 | +84% | 0.48% | $45,196,925 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.9% | 1,899,661 | +23% | 0.05% | $43,692,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 1,838,208 | +16% | 0% | $42,287,465 |
| MORGAN STANLEY | 1.9% | 1,826,295 | +101% | 0% | $42,004,816 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1.8% | 1,749,268 | -19% | 0.16% | $40,233,164 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 1,554,366 | -33% | 0% | $35,751,000 |
| Aberdeen Group plc | 1.5% | 1,469,951 | +51% | 0.05% | $33,808,873 |
| GW&K Investment Management, LLC | 1.4% | 1,375,407 | +20% | 0.27% | $31,634,000 |
| AQR CAPITAL MANAGEMENT LLC | 1.4% | 1,360,497 | +82% | 0.02% | $31,291,431 |
| Rock Springs Capital Management LP | 1.3% | 1,267,241 | +1.7% | 1.5% | $29,146,543 |
| NORGES BANK | 1.3% | 1,261,026 | 0% | $29,003,598 | |
| Pictet Asset Management Holding SA | 1.3% | 1,231,331 | -16% | 0.03% | $26,563,176 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,213,928 | +85% | 0% | $27,920,333 |
| JANE STREET GROUP, LLC | 1% | 1,021,499 | +188% | 0.03% | $23,494,477 |
Institutional Holders of Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 7,948,054 | $165,488,430 | -$12,492,276 | $20.95 | 74 |
| 2025 Q4 | 93,871,464 | $2,156,995,771 | -$89,024,892 | $23.00 | 284 |
| 2025 Q3 | 95,480,928 | $2,872,333,685 | -$30,390,841 | $30.08 | 301 |
| 2025 Q2 | 94,131,376 | $3,423,160,510 | +$191,188,547 | $36.36 | 307 |
| 2025 Q1 | 88,841,861 | $3,218,915,813 | +$30,616,617 | $36.21 | 297 |
| 2024 Q4 | 87,497,812 | $3,681,153,433 | +$1,949,206 | $42.07 | 309 |
| 2024 Q3 | 86,896,233 | $4,824,969,188 | -$72,319,917 | $55.55 | 299 |
| 2024 Q2 | 88,212,580 | $3,625,598,894 | +$337,028,289 | $41.10 | 273 |
| 2024 Q1 | 79,925,459 | $3,729,060,008 | -$19,184,689 | $46.69 | 268 |
| 2023 Q4 | 80,397,353 | $3,844,802,509 | +$498,492,380 | $47.82 | 236 |
| 2023 Q3 | 70,612,041 | $2,517,056,820 | +$10,459,486 | $35.65 | 219 |
| 2023 Q2 | 69,514,116 | $3,206,303,623 | +$38,331,356 | $46.13 | 239 |
| 2023 Q1 | 68,735,803 | $2,755,924,776 | +$28,159,264 | $40.10 | 227 |
| 2022 Q4 | 68,068,127 | $3,153,029,340 | +$13,205,113 | $46.33 | 225 |
| 2022 Q3 | 67,920,512 | $2,812,302,784 | -$149,070,496 | $41.41 | 223 |
| 2022 Q2 | 67,540,585 | $4,030,154,883 | +$24,063,212 | $59.66 | 210 |
| 2022 Q1 | 67,087,441 | $4,870,684,649 | -$37,258,962 | $72.62 | 227 |
| 2021 Q4 | 67,646,883 | $5,688,385,130 | +$80,515,709 | $84.09 | 224 |
| 2021 Q3 | 66,666,465 | $6,012,124,489 | +$97,920,619 | $90.19 | 217 |
| 2021 Q2 | 65,481,898 | $6,240,143,536 | -$246,149,121 | $95.35 | 235 |
| 2021 Q1 | 67,877,270 | $7,730,039,829 | +$45,641,218 | $113.86 | 244 |
| 2020 Q4 | 67,658,657 | $9,366,525,048 | +$640,902,584 | $138.43 | 247 |
| 2020 Q3 | 63,092,193 | $5,187,430,003 | -$8,503,385 | $82.19 | 199 |
| 2020 Q2 | 63,208,158 | $4,944,359,312 | +$242,670,060 | $78.22 | 185 |
| 2020 Q1 | 60,196,473 | $2,674,187,064 | +$87,973,460 | $44.43 | 166 |
| 2019 Q4 | 57,960,233 | $2,475,997,749 | -$30,518,994 | $42.71 | 162 |
| 2019 Q3 | 58,743,550 | $2,513,000,802 | -$3,746,657 | $42.78 | 164 |
| 2019 Q2 | 58,918,990 | $3,740,916,935 | +$48,975,164 | $63.50 | 165 |
| 2019 Q1 | 58,332,415 | $4,045,800,203 | +$544,963,218 | $69.36 | 170 |
| 2018 Q4 | 50,637,251 | $2,201,420,429 | -$8,455,097 | $43.48 | 155 |
| 2018 Q3 | 49,753,360 | $3,798,517,088 | +$72,495,753 | $76.34 | 171 |
| 2018 Q2 | 48,810,187 | $3,751,960,915 | +$16,214,593 | $76.87 | 151 |
| 2018 Q1 | 48,941,898 | $2,495,515,451 | +$366,583,930 | $50.99 | 159 |
| 2017 Q4 | 43,222,558 | $2,004,746,148 | +$107,302,956 | $46.38 | 154 |
| 2017 Q3 | 40,596,743 | $2,164,481,778 | -$37,427,143 | $53.26 | 148 |
| 2017 Q2 | 41,247,736 | $2,557,116,579 | +$26,416,443 | $62.11 | 154 |
| 2017 Q1 | 40,725,846 | $2,759,699,220 | +$146,474,004 | $67.78 | 160 |
| 2016 Q4 | 41,627,417 | $2,926,846,973 | +$146,410,374 | $70.31 | 172 |
| 2016 Q3 | 39,527,653 | $2,802,274,760 | +$175,377,803 | $70.94 | 167 |
| 2016 Q2 | 36,785,323 | $1,799,227,912 | -$45,286,683 | $48.91 | 153 |
| 2016 Q1 | 37,365,438 | $2,365,011,412 | +$86,675,812 | $63.31 | 159 |
| 2015 Q4 | 35,576,368 | $3,991,057,622 | +$35,682,868 | $112.18 | 165 |
| 2015 Q3 | 35,309,662 | $3,400,791,001 | +$270,511,040 | $96.31 | 156 |
| 2015 Q2 | 32,519,914 | $3,330,261,876 | +$95,161,030 | $102.39 | 150 |
| 2015 Q1 | 31,628,609 | $1,962,983,846 | +$227,346,470 | $62.09 | 126 |
| 2014 Q4 | 27,930,073 | $1,225,534,642 | +$58,809,022 | $43.88 | 98 |
| 2014 Q3 | 26,496,419 | $1,499,696,849 | +$542,429,017 | $56.60 | 98 |
| 2014 Q2 | 16,922,876 | $747,921,361 | +$55,850,290 | $44.89 | 81 |
| 2014 Q1 | 15,678,184 | $746,820,000 | +$746,820,000 | $48.89 | 77 |